<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="75585">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01951144</url>
  </required_header>
  <id_info>
    <org_study_id>B7431001</org_study_id>
    <nct_id>NCT01951144</nct_id>
  </id_info>
  <brief_title>A First In Human Study In Healthy People To Evaluate Safety, Toleration, Pharmacokinetics and Pharmacodynamics of Single Oral Doses Of PF-06372865</brief_title>
  <official_title>A Double Blind (3rd Party Open) Randomized, Placebo Controlled, Crossover Dose Escalation Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of PF-06372865 in Healthy Male and Female Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Pfizer</source>
  <oversight_info>
    <authority>Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study in healthy people is to evaluate safety, toleration and time
      course of plasma concentration of single oral doses of PF-06372865. The pharmacodynamic
      activity of PF-06372865 will also be assessed. The effect of food on PK and the PK of
      PF-06372865 administered as a tablet formulation may also be investigated.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>October 2013</start_date>
  <completion_date type="Anticipated">July 2014</completion_date>
  <primary_completion_date type="Anticipated">July 2014</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science</study_design>
  <primary_outcome>
    <measure>Maximum Observed Plasma Concentration (Cmax)</measure>
    <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to Last Quantifiable Concentration (AUClast)</measure>
    <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to Extrapolated Infinite Time</measure>
    <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Oral Clearance (CL/F)</measure>
    <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Apparent Volume of Distribution (Vz/F)</measure>
    <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasma Decay Half-Life (t1/2)</measure>
    <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Area Under the Curve From Time Zero to 24 hours</measure>
    <time_frame>0, 0.25, 0.5, 1, 1.5, 2, 4, 6, 8, 12, 16, 24, 36, 48, 72, 96 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Saccadic Eye Movements (saccadic reaction time, saccadic peak velocity and saccadic inaccuracy)</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 4, 6, 12 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Body Sway</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 4, 6, 12 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Smooth Pursuit</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 4, 6, 12 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Bond and Lader VAS</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 4, 6, 12 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Adaptive Tracking</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 4, 6, 12 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Visual Verbal Learning Test</measure>
    <time_frame>1 and 6 hours post dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Pharmaco-EEG</measure>
    <time_frame>0, 0.5, 1, 1.5, 2, 4, 6, 12 hours post-dose</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">42</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>Cohort 1:</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending doses of PF-06372865 or placebo to investigate the safety/tolerability PK and PD of PF-06372865.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2:</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending doses of PF-06372865 or placebo to investigate the safety/tolerability PK and PD of PF-06372865.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3:</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single ascending doses of PF-06372865 or placebo to investigate the safety/tolerability PK and PD of PF-06372865.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4 (optional cohort):</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Two single doses of PF-06372865 or placebo or lorazepam to further investigate the pharmacodynamics of PF-06372865.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06372865 or Placebo</intervention_name>
    <description>PF-06372865 will be administered as an extemporaneously prepared solution for all doses unless the tablet formulation need to be evaluated. Correspondingly, placebo doses will be administered as solution or tablet.</description>
    <arm_group_label>Cohort 1:</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06372865 or Placebo</intervention_name>
    <description>PF-06372865 will be administered as an extemporaneously prepared solution for all doses unless the tablet formulation need to be evaluated. Correspondingly, placebo doses will be administered as solution or tablet.</description>
    <arm_group_label>Cohort 2:</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06372865 or Placebo</intervention_name>
    <description>PF-06372865 will be administered as an extemporaneously prepared solution for all doses unless the tablet formulation need to be evaluated. Correspondingly, placebo doses will be administered as solution or tablet.</description>
    <arm_group_label>Cohort 3:</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PF-06372865 or Placebo or Lorazepam</intervention_name>
    <description>Lorazepam 2 mg dose, PF-06372865 and placebo administered as tablet formulation</description>
    <arm_group_label>Cohort 4 (optional cohort):</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy male subjects or female subjects of non-child bearing potential between the
             ages of 18 and 55 years, inclusive.

          -  Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight &gt;50 kg (110
             lbs).

          -  An informed consent document signed and dated by the subject

          -  Subjects who are willing and able to comply with scheduled visits, treatment plan,
             laboratory tests, and other study procedures.

        Exclusion Criteria:

          -  Evidence or history of clinically significant hematological, renal, endocrine,
             pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or
             allergic disease (including drug allergies, but excluding untreated, asymptomatic,
             seasonal allergies at time of dosing).

          -  Any condition possibly affecting drug absorption (e.g., gastrectomy).

          -  A positive urine drug screen.
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <role>Study Director</role>
    <affiliation>Pfizer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Pfizer CT.gov Call Center</last_name>
    <phone>1-800-718-1021</phone>
  </overall_contact>
  <location>
    <facility>
      <name>Pfizer Investigational Site</name>
      <address>
        <city>Leiden</city>
        <state>CL</state>
        <zip>2333</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=B7431001&amp;StudyName=A%20First%20In%20Human%20Study%20In%20Healthy%20People%20To%20Evaluate%20Safety%2C%20Toleration%2C%20Pharmacokinetics%20and%20Pharmacodynamics%20of%20Single%20Oral%20Doses%20</url>
    <description>To obtain contact information for a study center near you, click here.</description>
  </link>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 21, 2014</lastchanged_date>
  <firstreceived_date>September 13, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>Single Dose</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Safety</keyword>
  <keyword>Toleration</keyword>
  <keyword>Pharmacodynamics</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lorazepam</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
